Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Vestal Point Capital LP

Vestal Point Capital LP grew its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 105.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,150,000 shares of the company's stock after purchasing an additional 590,000 shares during the quarter. Structure Therapeutics makes up approximately 3.8% of Vestal Point Capital LP's holdings, making the stock its 6th biggest position. Vestal Point Capital LP owned about 2.01% of Structure Therapeutics worth $50,474,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of GPCR. Virtu Financial LLC purchased a new stake in shares of Structure Therapeutics during the 1st quarter valued at about $308,000. Teachers Retirement System of The State of Kentucky boosted its stake in shares of Structure Therapeutics by 17.8% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company's stock valued at $589,000 after purchasing an additional 2,077 shares during the period. Mather Group LLC. bought a new position in shares of Structure Therapeutics in the second quarter worth about $214,000. Principal Financial Group Inc. purchased a new position in Structure Therapeutics in the 2nd quarter worth about $6,489,000. Finally, Natixis Advisors LLC lifted its holdings in Structure Therapeutics by 29.4% during the 2nd quarter. Natixis Advisors LLC now owns 19,005 shares of the company's stock valued at $746,000 after buying an additional 4,321 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GPCR has been the topic of a number of research reports. JMP Securities reduced their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating on the stock in a research report on Friday, August 9th. Morgan Stanley assumed coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an "overweight" rating and a $118.00 target price for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $86.80.

Structure Therapeutics Trading Down 1.8 %

Shares of GPCR traded down $0.60 during trading hours on Friday, hitting $33.15. The company had a trading volume of 240,485 shares, compared to its average volume of 783,041. The company has a market capitalization of $1.90 billion, a PE ratio of -44.80 and a beta of -3.23. Structure Therapeutics Inc. has a one year low of $26.61 and a one year high of $66.38. The company's fifty day moving average price is $38.39 and its two-hundred day moving average price is $39.42.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.